Tag Archives: nasdaq

Market Lab Report – Premarket Pulse 11/5/15

Major averages fell mildly on mixed volume. So far the indexes have not shown any tendency to pull back more than a couple of days before pushing to higher highs, and larger-cap names that have issued buy signals over the past few weeks following earnings have continued to act well and move higher. With the Russell 2000 now joining the party as it pushes to higher highs and approaches its 200-day moving average, more smaller- to mid-cap names are starting to participate. With US Fed Chairperson Yellen saying there is a “live possibility” of a rate hike in December, CME FedWatch now places the odds of a rate hike at 56% at that next meeting. A few new actionable names hit our screens yesterday. Keep in mind that while the number of such stocks over the last several days has been sizeable, a number of them are not moving higher despite the uptrending market. This is a yellow flag that warrants caution as not all cylinders are firing as they should. Instead, institutional money is flowing primarily into the risk-off, largest cap names as witnessed by the NASDAQ-100 being the first index to hit new highs. Information technology hardware and software product maker CDW Corp. (CDW) had a pocket pivot yesterday on a strong earnings report. Earnings are accelerating, ROE 49.7%, institutional sponsorship has grown in every quarter since the company went public 10 quarters ago, group rank 5. Web-based and mobile fleet management software maker Fleetmatics Group (FLTX) gapped up yesterday on a strong earnings report, then fell but then returned to its gap up price at which time this report was sent. Pretax margin 21.9%, group rank 21. Cloud-based human capital management software maker Paycom Software (PAYC) had a buyable gap up yesterday on a strong earnings report. ROE 24.1%, Earnings and sales are soaring, institutional sponsorship has grown over the last 3 quarters, group rank 21. Facebook (FB) is gapping up this morning after beating on earnings last night. We will be monitoring this for a possible buyable gap-up, and issue a report as appropriate.

Top ETF Stories To Watch For In November

The third quarter of 2015 was shockingly downbeat for the broader U.S. market and the global indices with the China-led tumult culminating into a bloodbath in August and September. Needless to say, investors will keenly watch the market movement in the fourth quarter. With the first month of Q4 finally bringing back the strong stretch for the U.S. market, investors must now be hoping for more and seeking to carve out some solid gains. Traditionally, the three months from November through January mark the most successful run of the stock market. A consensus carried out from 1950 to 2014 shows that November ended up offering positive returns in 43 years and negative returns in 22 years, per moneychimp.com . In fact, all the three major indices are now positive from the year-to-date look with the S&P 500 rising 2.5%, Dow Jones Industrials Average gaining over 0.5% and Nasdaq composite climbing 8.6%. With vacations, holiday season buying and seasonal optimism taking charge, investors might reap more returns to close out 2015. However, before riding on the cyclicality, one should not cast out the presently-hot areas of the global investing arena, which will play the kingmakers in November. This is why we highlight the top financial stories and the related ETFs which should be strongly watched this month. Fed Rate Lift-off Talks and Rising U.S. Bond Yields Turning on rounds of hearsay about the lift-off, the Fed brought the December rate hike possibility back on to the table in October end. Yes, the central bank is supportive now, citing a slowing job market, moderating U.S. economic growth and subdued inflation. But it was finally the easing of the upheaval in the global market that led it to mull over policy tightening this year, if possible. Post Fed meeting at October end, investors rapidly shifted their bets with futures contracts entailing a 52% December hike possibility (at the current level) compared with 34% preceding the statement. In anticipation of a faster lift-off, the 10-year Treasury bond yields jumped 18 bps to 2.23% in six days (as of November 3, 2015). The rising yields give cues of the fact that though Q3 U.S. economic growth tallied 1.5 % in Q3, falling short of the 1.6% expectation, investors are hardly paying heed to the soft GDP data, rather wagering on a sooner-than-expected lift-off. As a result, sectors benefitting from higher rates showed strength in recent trading. Financial ETFs like SPDR S&P Regional Banking ETF (NYSEARCA: KRE ) and U.S. dollar ETF PowerShares DB US Dollar Bullish Fund (NYSEARCA: UUP ) performed nicely and could be in watch this month. High Yield Bond ETFs Back into Business After having a troublesome time in the first half of the year, the scope of outperformance for the high-yield bond ETFs is now opening up. Investors seeking to beat the yields provided by the benchmark U.S. treasury bonds might flock to this segment. Corporate bonds are also showing an uptrend on rising issuance. In October, as much as $ 100 billion worth of U.S. corporate bonds were sold. This dynamics in the high-risk fixed-income market should put bonds like BulletShares 2016 High Yield Corporate Bond ETF (NYSEARCA: BSJG ), High Yield Long/Short ETF (NASDAQ: HYLS ) and High Yield Interest Rate Hedged ETF (BATS: HYHG ) in focus. Biotech Bounce The biotech space saw choppy trading in the past few weeks on drug pricing concerns. While the sell-off made the space affordable, a few more days of easy money from the Fed should be supportive of this high-beta sector. Needless to say, the operating fundamentals of the biotech space are stronger than many other sectors. As a result, ETFs like Dynamic Biotech & Genome ETF (NYSEARCA: PBE ), SPDR S&P Biotech ETF (NYSEARCA: XBI ) and ALPS Medical Breakthroughs ETF (NYSEARCA: SBIO ) would be in focus throughout this month. Inside the Chinese Wall Now who can forget China? Surprises and shocks from the world’s second largest economy are rampant these days. In October, China reduced the key interest rates by 25 bps which marked the sixth slash since last November. Apart from these, China enacted a volley of accommodative measures to boost domestic consumption. Of which, scrapping of its long-standing ‘one-child’ policy was eye-catching. Since, the so-far-rolled-out measures to jumpstart the ailing economy went down the drain, investors can very well expect some other stimulus measures this month. Chinese ETFs including Market Vectors ChinaAMC SME-ChiNext ETF (NYSEARCA: CNXT ) and iShares MSCI China Small-Cap ETF (NYSEARCA: ECNS ) are worth a watch. European Delight Though Q3 was patchy for the continent, Q4 has so far been joyous for the European region. No, economic data hasn’t been great; but it is ECB’s promise to beef up the ongoing QE measure (if need be) that has started showering gains on the European stocks and ETFs. As a result, all currency-hedged European ETFs including Europe Hedged SmallCap Equity Fund (NYSEARCA: EUSC ), Europe Hedged Equity Fund (NYSEARCA: HEDJ ) and Currency Hedged MSCI Germany ETF (NYSEARCA: HEWG ) are set for a northbound journey since last month and are likely to top investors’ list in November too. Original Post

3 Common Backtesting Traps With Easy Solutions

Backtests have become the weapon of choice for rationalizing various forms of tactical asset allocation, which has become increasingly popular as a risk-management tool since the 2008 crash. The hazards of backtesting – studying how a strategy performed in the past – are well known, which leads some folks to shun the concept entirely. But that’s going too far. In some respects, every investment plan owes a debt to some type of backtesting – even for a buy-and-hold strategy, which assumes that the future will deliver gains on par with what was earned in the past. The proper lesson is that designing robust backtests, which demands close attention to detail. Easier said than done, of course, in part because the pitfalls can be subtle. Here are three that routinely trip up the novice and perhaps even some experienced investors: The use of total return prices for technical signals; Failing to correct for look-ahead bias by not using lagged signals; and Overlooking the importance of neutral signals for computing backtest results. The good news is that these traps are easily avoided. But there’s a catch: you have to be aware of the hazards. With that in mind, let’s briefly review these backtesting snares with some simple examples. Total return data. Imagine that you’ve created what you think of as a winning investment strategy that’s based on two signals: a) the ratio for a set of short and long moving averages; b) the trailing return for a rolling x-day window. The results look encouraging, but the upbeat outcome may be an illusion if the calculations use total return prices. Why? Consider a mutual fund that’s unchanged on the day but dispenses a hefty distribution at the close of trading. Imagine that this fund is priced at $10 a share and it spits out a 50-cent-per-share payout. Although the underlying portfolio value was unchanged on the day the mutual fund’s price falls by 50 cents to $9.50 to compensate for the distribution. The net result for shareholders: their holdings in the fund remain unchanged on the day. The 50-cent-per-share drop is offset by a 50-cent distribution. In short, a net wash. It’s a routine affair in day-to-day market activity, but it’s a trap if you’re looking at a fund’s technical profile without adjusting for distributions. Let’s say that the 50-cent price decline pushes the fund into negative territory in terms of the short/long moving average ratio and trailing x-day return. On the surface, this looks like a sell signal when, in fact, it’s nothing of the sort since the fund’s portfolio value hasn’t changed. The solution is to use price data that strips out distributions. If you don’t make that adjustment, your backtests using technical signals are probably faulty. Keep in mind too that the total return price histories aren’t real in the sense that the prices have been retroactively adjusted down to compensate for dividends, capital gains, etc. In other words, total return prices weren’t available in real time through history. Ignoring this issue runs the risk that your backtests are telling lies. Lagged signals & avoid look-ahead bias. This is another common mistake that can turn a sow’s ear into pearls, if only on paper. There are many variations to this trap depending on the complexity of the strategy, but the basic form can be illustrated with a simple example. Take a strategy that issues a “sell” signal when price falls below an x-day moving average and a “buy” when price rises above that average. Let’s also assume that we’re using end-of-day closing prices. You test the strategy and discover that it delivers a strong performance through time. But you forget one small item: the end-of-day signals aren’t available until after the market closes. In other words, calculating returns for a real-world version of the strategy requires using lagged “buy” and “sell” signals. One solution: assume a one-day lag. A “sell” signal is issued at Monday’s close, which translates to assuming that security was sold at the following day’s close. How much difference will such a seemingly minor change make in a strategy’s results? A lot. Indeed, many strategies that look wonderful in backtests turn into dogs after correcting for look-ahead bias. Neutral signals. This is an especially subtle problem because it’s counterintuitive in some respects. The problem is when there’s a gray area with one or more trading signals. For instance, let’s say you’re using two signals to determine if the current climate for an asset is bullish or bearish. A “buy” is when both signals are bullish; a “sell” is when both are bearish. If there’s a split decision – one is bullish, the other bearish – the signal is neutral, which is to say that the previous signal holds until both signals indicate a decisive change, one way or the other. As an example, both signals issued a “buy” signal the first trading day of the month. Two weeks later one of the signals turns bearish but there’s no confirmation in the other signal, which continues to align with a bullish reading. The net result: we no longer have a “buy” signal, but there’s no “sell” signal either. In that case, the previous signal – a “buy” – remains in force until a “sell” signal arrives. Obvious? Well, sure, once we spell it out and are aware of the subtlety. But designing this nuance into the code can trip up a rookie. The solution: generate a historical record of “buy” and “sell” signals and monitor the net result via a “position” signal. A standard system is to generate a “1” for “buy”, “0” for netural, and “-1” for “sell” in the “position” data. By contrast, a common mistake is to only calculate the “buy” signals and assume that the absence of a “buy” is the equivalent of “sell”. Not necessarily, but that won’t be obvious unless you compute a separate set of “sell” and “neutral” signals. What’s the relevance? Results. A backtest that equates “neutral” with “buy” signals can and usually does dispense substantially different results vs. a test that recognizes the distinction. Okay, maybe you want to blur the lines for tactical reasons. That’s fine. The danger arises when the analyst doesn’t spot the difference in advance. These are hardly the only pitfalls in backtesting, but they’re relatively common – and easily avoided. The question is whether these quantitative stumbles have skewed results in some of the more influential backtests that have found a wide audience in recent years? The answer: unclear until (if) we can reproduce the research. Unfortunately, most of the backtests that make the rounds these days don’t provide the accompanying code. That’s one more reason why it’s essential to crunch the numbers directly before making substantial monetary commitments to a given strategy. As President Reagan famously advised, Trust but Verify. That’s a good policy for geopolitical negotiations and for backtesting investment strategies.